{
    "clinical_study": {
        "@rank": "80757", 
        "arm_group": [
            {
                "arm_group_label": "Immediate release capsule(lyrica capsule 150mg)", 
                "arm_group_type": "Active Comparator", 
                "description": "Immediate release capsule repeat treatment for 3days under fasted condition"
            }, 
            {
                "arm_group_label": "sustained release tablet", 
                "arm_group_type": "Experimental", 
                "description": "sustained release tablet repeat treatment for 3days under fasted condition"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the pharmacokinetics profiles of pregabalin\n      sustained release tablet (300mg) to immediate release capsule(150mg * 2) while multiple\n      dosing."
        }, 
        "brief_title": "Clinical Trial to Compare The Pharmacokinetics of A Pregabalin Controlled Release Tablet 300mg and Immediate Release Formulation", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Neuropathic Pain", 
        "condition_browse": {
            "mesh_term": "Neuralgia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  19~44 aged healthy adult.\n\n          -  someone tho has at least 50kg body weight and ideal body weight \u00b120%\n\n        Exclusion Criteria:\n\n          -  someone has acute symptom at screening phase\n\n          -  someone has any disease or symptoms which is clinically significant\n\n          -  someone had been determined during healthy examination in screening period\n\n          -  AST or ALT > 1.25 times than normal\n\n          -  Total bilirubin > 1.5 times than normal\n\n          -  someone who has a history of allergy, anaphylaxis, drug abuse or misuse.\n\n          -  someone who had enrolled to other clinical trial within the last 60 days.\n\n          -  someone who had donated blood within the last 60 days.\n\n          -  someone who can't take a meal derived from this trial.\n\n          -  someone who has taken abnormal meals like which can affect to drug ADME\n\n          -  someone who has taken other ETC drugs or oriental drugs within the last 14 days, Or\n             OTC drugs within the last 7 days\n\n          -  someone who has taken caffein continuously (coffee or green tea more than 5 cups per\n             a day) or took caffein since 24hours before.\n\n          -  someone who has taken alcohol more than 30g/day or smoked more than 10 piece of\n             tobacco/day.\n\n          -  someone who has galactose intolerance, Lapp lactase deficiency or glucose-galactose\n             malabsorption."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "44 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02103647", 
            "org_study_id": "ID-PRMD-1202"
        }, 
        "intervention": [
            {
                "arm_group_label": "Immediate release capsule(lyrica capsule 150mg)", 
                "description": "Immediate release capsule", 
                "intervention_name": "Immediate release capsule(lyrica 150mg * 2/day)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "sustained release tablet", 
                "description": "sustained release tablet", 
                "intervention_name": "sustained release tablet", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Pregabalin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Neuropathic pain", 
            "pregabalin"
        ], 
        "lastchanged_date": "April 1, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "state": "Seocho-gu"
                }, 
                "name": "Catholic medical center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open-label, Crossover Clinical Trial to Compare The Pharmacokinetics of A Pregabalin Controlled Release Tablet 300mg and Immediate Release Formulation After Multiple Dosing Under Fasted Condition in Healthy Male Subjects", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Measure blood concentration of pregabalin", 
            "safety_issue": "No", 
            "time_frame": "0~4day / 14~18day"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02103647"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Safety evaluation", 
            "safety_issue": "Yes", 
            "time_frame": "0~25day"
        }, 
        "source": "IlDong Pharmaceutical Co Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "IlDong Pharmaceutical Co Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}